<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2026-01-15</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2026-01-15</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>71</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
æ–°å‹å››ä»·CAR-å·¨å™¬ç»†èƒç–«è‹—åœ¨å°é¼ æ¨¡å‹ä¸­å±•ç°å‡ºå…‹æœè‚¿ç˜¤å¼‚è´¨æ€§ã€æŠ‘åˆ¶å®ä½“ç˜¤çš„æ½œåŠ›ï¼›dCas9ä»‹å¯¼çš„DNAç”²åŸºåŒ–ç¼–è¾‘ç³»ç»Ÿåœ¨ç‰¹å¼‚æ€§å’Œç¨³å®šæ€§æ–¹é¢è¿›è¡Œäº†ç³»ç»Ÿæ€§æ¯”è¾ƒã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚¿ç˜¤å…ç–«æ²»ç–—ï¼šå¼€å‘CAR-å·¨å™¬ç»†èƒç–«è‹—ï¼Œæ¢ç´¢TCR-Tç»†èƒçš„æŠ—è‚¿ç˜¤åŠŸèƒ½å¢å¼ºç­–ç•¥ï¼Œç ”ç©¶Î³Î´ Tç»†èƒåœ¨æºƒç–¡æ€§ç»“è‚ ç‚ä¸­çš„ä½œç”¨ã€‚<br />
- è‚¿ç˜¤å‘ç”Ÿä¸è€è¯æœºåˆ¶ï¼šæ¢ç©¶IDHçªå˜èƒ¶è´¨ç˜¤çš„èµ·æºç»†èƒï¼Œè§£æROR1-PI3K/AKTä¿¡å·é€šè·¯åœ¨åµå·¢ç™Œè€è¯ä¸­çš„ä½œç”¨ï¼Œç ”ç©¶ARé¶å‘ç–—æ³•ä¸PARPæŠ‘åˆ¶å‰‚åœ¨<strong>åŒæºé‡ç»„ä¿®å¤ç¼ºé™·ï¼ˆHRDï¼‰</strong>é˜³æ€§å‰åˆ—è…ºç™Œä¸­çš„ååŒæ€§ã€‚<br />
- è¡¨è§‚é—ä¼ è°ƒæ§ï¼šç ”ç©¶DAXXåœ¨é›„æ€§ç”Ÿæ®–ç»†èƒå½¢æˆè¿‡ç¨‹ä¸­è°ƒæ§ç»„è›‹ç™½æ›¿æ¢çš„æœºåˆ¶ï¼Œè¯„ä¼°dCas9ä¸ºåŸºç¡€çš„DNAç”²åŸºåŒ–ç¼–è¾‘ç³»ç»Ÿçš„æ€§èƒ½ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- ç©ºé—´è½¬å½•ç»„å­¦æŠ€æœ¯ç”¨äºè§£æè‚¿ç˜¤å¾®ç¯å¢ƒçš„ç»†èƒèµ·æºã€‚<br />
- é«˜é€šé‡æµ‹åºæŠ€æœ¯ï¼ˆåŒ…æ‹¬å•ç»†èƒæµ‹åºï¼‰åœ¨æ­ç¤ºç»†èƒäºšç¾¤å¤šæ ·æ€§ã€åŸºå› è¡¨è¾¾è°±å’ŒæŸ“è‰²è´¨ç»“åˆæ¨¡å¼æ–¹é¢å¾—åˆ°å¹¿æ³›åº”ç”¨ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
ç ”ç©¶é¦–æ¬¡ç»˜åˆ¶å‡ºå¤šå‘æ€§éª¨é«“ç˜¤æ‚£è€…éª¨é«“ä¸­æœ€å¤§çš„å…ç–«ç»†èƒå›¾è°±ï¼Œå¹¶å¼€å‘å‡ºæ–°å‹RNAæµ‹åºæŠ€æœ¯ï¼Œèƒ½ç²¾å‡†æ£€æµ‹ä½“ç»†èƒå•æ ¸è‹·é…¸å˜å¼‚ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- ç»˜åˆ¶å¤šå‘æ€§éª¨é«“ç˜¤æ‚£è€…éª¨é«“å…ç–«ç»†èƒå›¾è°±ï¼Œé¢„æµ‹å¤å‘é£é™©ã€‚<br />
- æ£€æµ‹é˜¿å°”èŒ¨æµ·é»˜ç—…çš®è´¨ä¸­çš„ä½“ç»†èƒçªå˜ï¼Œæ­ç¤ºå˜å¼‚ä½œç”¨ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- å•ç»†èƒRNAæµ‹åºç»˜åˆ¶è¿‘150ä¸‡ä¸ªéª¨é«“å…ç–«ç»†èƒå›¾è°±ã€‚<br />
- RNA-MosaicHunteræŠ€æœ¯ç²¾å‡†æ£€æµ‹ä½“ç»†èƒå•æ ¸è‹·é…¸å˜å¼‚ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (69æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE316356 ä½“å†…å››ä»·CAR-å·¨å™¬ç»†èƒä½œä¸ºç»†èƒç–«è‹—ï¼Œå¯é€šè¿‡æŠ—åŸæ‰©æ•£æŠ‘åˆ¶å®ä½“ç˜¤å¹¶å…‹æœè‚¿ç˜¤å¼‚è´¨æ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€vaccineã€macrophageã€antigen<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Shaolong Zhang ; Hengxing Lu ; Hailing Zhang ; Qixin Wu ; Xizhong DingSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Mus musculusWe designed a quadrivalent in vivo CAR-engineered macrophage for treating solid tumors by the LNP-mRNA system. Mechanically, we found that in vivo engineered CAR macrophages can promote the formation of T-cell immune memory against neoantigens through antigen spreading. To further elucidate this phenomenon, we treated orthotopic HCC model mice with PBS, LNP-GPC3 CAR, or LNP-GPC3 CAR-Super IL-2 and subsequently collected splenocytes from these three groups for transcriptomic and TCR sequencing analyses. Based on data from transcriptome and TCR sequencing, we propose a two-signal model for T-cell activation: the GPC3 CAR provides the primary signal by recognizing and presenting tumor antigens, while the secreted Super IL-2 supplies the additional signal necessary for robust T-cell clonal expansion. These findings provide novel mechanistic insights into the anti-tumor activity of in vivo engineered CAR macrophages.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316356" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE302642 IDHçªå˜å‹èƒ¶è´¨ç˜¤èµ·æºäºæºå¸¦åˆå§‹é©±åŠ¨çªå˜çš„èƒ¶è´¨ç¥–ç»†èƒï¼ˆç›¸å…³ç™»å½•å·ï¼šGSE275791ï¼‰â€”â€”ç©ºé—´è½¬å½•ç»„å­¦æ•°æ®é›†</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šspatialã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Jung Won Park ; Jeong Ho LeeSeries Type : OtherOrganism : Homo sapiensDiscovering the cell-of-origin harboring the initial driver mutation provides a fundamental basis for understanding tumor evolution and development of new treatments. For isocitrate dehydrogenase (IDH)-mutant gliomasâ€“the most common malignant primary brain tumors in adults under 50â€“the cell-of-origin remains poorly understood. Here, using patient brain tissues and genome-edited mice, we identified glial progenitor cells (GPCs), including oligodendrocyte progenitor cells (OPCs), as the glioma-originating cell type harboring the IDH mutation as the initial driver mutation. We conducted comprehensive deep sequencing, including droplet digital PCR and deep panel and amplicon sequencing to 142 tissues from 70 patients (32 IDH-mutant gliomas and 38 IDH-negative controls) comprising tumors, histologically normal peritumoral regions or subventricular zones (SVZs), and blood. Surprisingly, low-level IDH mutation was found in the normal peritumor away from the tumor in 37.9% (11 of 29) of IDH-mutant glioma patients, whereas no IDH mutation was detected in the SVZ. Integrating cell-typeâ€“specific mutations analysis, the direction of clonal evolution, spatial transcriptomics from patient brains and a novel IDH-mutant glioma mouse model arising from mutant OPCs, we determined that GPCs, including OPCs, harboring the initial driver mutation are responsible for the development and evolution of IDH-mutant gliomas. In summary, our results demonstrate that GPCs containing the IDH mutation are the cells-of-origin harboring the initial driver mutation in IDH-mutant gliomas.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302642" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE314261 åœ£è£˜å¾·ç»ˆç”Ÿé˜Ÿåˆ—ä¸­å„¿ç«¥ç™Œç—‡å¹¸å­˜è€…æ²»ç–—å’Œç”Ÿå‘½å†ç¨‹æš´éœ²ä¸ä¸è‰¯å¥åº·ç»“å±€çš„å…¨åŸºå› ç»„DNAç”²åŸºåŒ–è°±åˆ†æ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€epigenomeã€methylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Methylation profiling by genome tiling arrayOrganism : Homo sapiensLong-term survivors of childhood cancer experience treatment-related cardiotoxicity among a broad spectrum of chronic health conditions, which may be further aggrevated by suboptimal life-course social/behavioral/environmental exposures. Epigenetic mechanisms, particularly DNA methylation (DNAm), provide a potential link through which these exposures become biologically embedded and subsequently influence long-term health outcomes. Epigenome-wide association studies (EWAS) identified DNAm signatures associated with both treatment effects as well as life-course exposures. In parallel, DNAm variations were also evaluated in relation to cardiometabolic risk factors, cardiovascular diseases, and other chronic health conditions, revealing individual CpG sites or genes/geomic regions where these CpGs reside linked to clinically relevant phenotypes. Together, these findings support DNAm as a molecular interface connecting diverse exposures to adverse health outcomes. In addition, epigenetic age acceleration, assessed using DNAm-based aging biomarkers, was observed among survivors exposed to cancer treatments. Epigenetic age acceleration mediated a substantial proportion of the associations between cancer treatment exposures and cardiometabolic risk factors or cardiovascular diseases, supporting accelerated biological aging as a key pathway linking cancer treatment to long-term morbidity. Lifestyle and health behaviors, as well as social vulnerability and psychosocial stress, were also associated with variations in epigenetic age acceleration, highlighting the potential modifiability of aging-related pathways in ameliorating late-effects among childhood cancer survivors. In conclusion, these findings establish DNAmâ€”captured through EWAS signatures and epigenetic age accelerationâ€”as central molecular mechanisms linking treatment effects and life-course exposures to cardiotoxicity along with other chronic health conditions in childhood cancer survivors. This integrative epigenetic framework supports the use of DNAm-based biomarkers for risk stratification and nominates modifiable pathways as potential intervention targets to improve long-term survivorship outcomes.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314261" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE315828 9-PAHSA è°ƒæ§ TCR-T ç»†èƒå‘½è¿ä»¥å¢å¼ºæŠ—è‚¿ç˜¤å…ç–«åŠ›</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immunityã€T cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Xiaozhen ZhangSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusWe identify the endogenous lipid 9-PAHSA as a potent enhancer of T cell anti-tumor function and stemness, validated in murine models and a clinical trial. Mechanistically, we identify ICAM2 as a direct surface sensor for 9-PAHSA and delineate a downstream signaling axis whereby the ICAM2-Ezrin-mTORC2 cascade drives FOXO1 O-GlcNAcylation at S318, facilitating its nuclear translocation to enact a stem-like transcriptional program. Translating this discovery, we engineered armored human TCR-T cells with potentiated ICAM2 expression, which achieve superior tumor control through their enhanced intrinsic efficacy and a remarkable ability to ignite a coordinated and durable host anti-tumor immune response. Our work establishes a new paradigm of metabolite-sensing in T cell biology and provides a compelling therapeutic strategy to potentiate cellular immunotherapy for intractable cancers.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315828" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>GSE316069 å•ç»†èƒåˆ†ææ­ç¤ºæºƒç–¡æ€§ç»“è‚ ç‚ä¸­Î³Î´ Tç»†èƒäºšç¾¤çš„å¤šæ ·æ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šT cellã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Jakob ArnoldSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Homo sapiensÎ³Î´ T cells maintain intestinal immune homeostasis, but their contributions to human ulcerative colitis (UC) are poorly understood. We characterized Î³Î´ T cells in intestinal biopsies obtained from patients with UC and healthy donors using single-cell RNA sequencing, T cell receptor profiling, and mass cytometry. UC reduced CD103+VÎ³4VÎ´1+ intraepithelial Î³Î´ lymphocytes (Î³Î´ IELs) and increased Î³Î´ T cell subsets with stem-like phenotypes expressing T cell factor-1 (TCF-1) and programmed cell death receptor 1 (PD-1), or effector-like phenotypes expressing granzyme B, perforin, and T-box expressed in T cells (T-bet). Î³Î´ T cell composition changes in UC correlated with decreased expression of epithelial BTNL3 and BTNL8 and increased BTN3A1 and BTN3A3 , suggesting altered recruitment and activation . Clinical improvement recovered Î³Î´ IELs and reduced inflammation-associated subsets. Inflammation-associated changes were observed in peripheral blood Î³Î´ T cells. Thus, distinct Î³Î´ T cell subsets in different niches exert protective or pathogenic functions in UC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316069" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>GSE315883 åŒæºé‡ç»„åŠŸèƒ½æ­£å¸¸çš„åˆ—è…ºç™Œä¸­ AR é¶å‘æ²»ç–—ä¸ PARP æŠ‘åˆ¶ä¹‹é—´ç¼ºä¹ååŒä½œç”¨ [ATAC-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€ATAC-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Nicole A Traphagen ; Myles BrownSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensRecent clinical trials have explored the combination of androgen receptor (AR) pathway inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors as a potential treatment for castration-resistant prostate cancer. This combination treatment is based on the premise that AR directly regulates expression of DNA repair genes, leading to synergy between PARP and AR inhibition. Despite some promising preclinical evidence, this combination therapy has shown limited efficacy in patients with homologous recombination (HR)-proficient tumors. To investigate this discrepancy between preclinical and clinical results, we profiled the effects of PARP inhibition in prostate cancer models in the presence or absence of AR inhibition. Surprisingly, AR inhibition impaired response to PARP inhibitors in castration-sensitive cells and had no effect on response in castration-resistant cells. AR inhibition also did not regulate DNA repair in either the castration-resistant or castration-sensitive setting. Instead, we find that cell cycle progression is required for response to PARP inhibition in homologous-recombination proficient prostate cancer.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315883" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>GSE308003 DAXX æŒ‡å¯¼ç²¾å­å‘ç”Ÿè¿‡ç¨‹ä¸­ H3.4 åˆ° H3.3 ç»„è›‹ç™½çš„æ›¿æ¢ [RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seqã€histone<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Satoshi H Namekawa ; Yu-Han YehSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusDuring spermatogenesis, extensive chromatin remodeling and histone replacement reshape the male germline epigenome. While HIRA is known to mediate transcription-coupled incorporation of histone variant H3.3, we identify DAXX as a key histone chaperone directing genome-wide, transcription-dependent replacement of H3.4 (H3T) with H3.3 on autosomes during male meiosis. Simultaneously, DAXX also directs transcription-independent H3.4-to-H3.3 replacement on the sex chromosomes during meiotic sex chromosome inactivation (MSCI). These distinct, chromosome-specific modes of DAXX-mediated H3.3 deposition are essential for epigenomic integrity in the male germline. Loss of DAXX disrupts this process, leading to widespread transcriptional dysregulation in haploid round spermatids and male infertility.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308003" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE297836 ROR1-PI3K/AKTä¿¡å·é€šè·¯é©±åŠ¨TP53çªå˜åµå·¢ç™Œå¯¹ç»†èƒå‘¨æœŸé˜»æ»çš„é€‚åº”æ€§è€è¯</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Frida Rantanen ; Alice Dini ; Harlan Barker ; Daniela UngureanuSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWe developed long-term resistant (lt-res, several months) pre-clinical models to adavosertib (ADA) and paclitaxel (PTX). We identified distinct transcriptomic and morphological changes in the ovarian cancer lt-res models. ADA resistance involves signaling pathway alterations that allow cells to maintain unchecked proliferation, while PTX resistance primarily stems from structural changes within the cell, affecting microtubules and drug efflux. Upregulation of receptor tyrosine kinases, such as ROR1, was observed in both ROR1-positive ADA and PTX lt-res models. Targeting ROR1 with zilovertamab-vedotin, a monoclonal antibody-drug conjugate, resulted in enhanced cytotoxicity, demonstrating a new approach against recurrent drug-resistant ovarian cancer.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297836" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE316347 å·¨å™¬ç»†èƒå…ç–«æ´»æ€§ç»“è‚ ç»„è£…ä½“ç”¨äºç¥ç»ç‚ç—‡è¯±å¯¼çš„ç»“è‚ è¿åŠ¨éšœç¢çš„åŠŸèƒ½ç ”ç©¶</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€macrophage<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Claudia Collier ; Karla Ortega Sandoval ; Aelita Salikhova ; Shrinarayanee Rengarajan ; Anvitha Tharakesh ; Alana Aristimuno Millan ; Shanthi Srinivasan ; Shreya A RaghavanSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusFunctional gastrointestinal disorders (FGIDs) affect âˆ¼40% of the global population and are frequently characterized by colonic dysmotility. Symptomatic manifestations of colonic dysmotility significantly reduce quality of life in inflammatory bowel disease (IBD), diabetes, and Gulf War Illness (GWI). Current in vitro models lack the integration of functional physiology with immune and neuronal complexity required to establish causal links between neuroinflammation and dysmotility. Here, an immune-competent bioengineered colon assembloid is introduced that integrates multiple cell types of the external colonic wall, along with functional readouts of motility. Within bioengineered colon assembloids, various inflammatory insults resulted in enteric neuroinflammation, cascading to changes in colonic motility. Key mechanisms of dysmotility following inflammatory insult within the bioengineered colon assembloids included impaired neuronal regeneration, and aberrant smooth muscle remodeling. The bioengineered colon assembloid model mimicked diverse aspects of enteric neuroinflammation. Ultimately, the platform offers a physiologically relevant avenue to interrogate neuroimmune crosstalk and dissect mechanisms of colonic dysmotility, paving the way to new therapeutic strategies to improve colonic motility.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316347" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE312264 é€šè¿‡éå…¸å‹è›‹ç™½æ¿€é…¶Cä¼˜åŒ–è‚ é“è‘¡è„ç³–å¼ åŠ›æ•ˆåº”</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼škinaseã€regex:intestin(e|al)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Chan Woo Kang ; Zhen-Yu Hong ; Hyeonuk Jeon ; Sungsoon Fang ; Insuk Sohn ; Cheol Ryong KuSeries Type : Expression profiling by high throughput sequencingOrganism : Rattus norvegicusIntestinal glucotonic transformation, defined as increased intestinal serum glucose uptake and secretion into the lumen, influences bariatric surgery-associated glycermic control. This study aims to identify downstream molecules that mediate the function of the identified target as an effective intestinjal glucotonic activator. Altered transcriptomes were evaluated in variable intestinal glucotonic models and big data-based drug discovery systems. Protein kinase C (PKC) activation mimicked transcriptome alterations observed during intestinal glucotonic transformation. Among the PKC subfamilies, atypical PKC (aPKC) promoted glucose transporter 1 (GLUT1)-mediated intestinal glucotonic transformation without inducing oncogenic proliferation. Intestinal aPKC activation via a transposon expression vector induced serum glucose uptake into intestinal tissues and excretion into the lumen. Prostratin, a non-tumorigenic phorbol ester, activated aPKC and induced a similar glucotonic effect. Collectively, we identified the prostratin and aPKC/GLUT1 signaling pathways as effective targets for treating diabetes, providing insights into the future development of antidiabetic and weight loss drugs.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312264" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 59 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (2æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨2æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>è¥¿å¥ˆå±±çš„ç ”ç©¶äººå‘˜å¸®åŠ©åˆ›å»ºäº†å¤šå‘æ€§éª¨é«“ç˜¤æ‚£è€…éª¨é«“ä¸­è§„æ¨¡æœ€å¤§çš„å…ç–«ç»†èƒå›¾è°±</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmune<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSingle-cell RNA sequencing maps nearly 1.5 million bone marrow immune cells in multiple myeloma, revealing immune dysfunction patterns that may help predict relapse risk...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/mount-sinai-researchers-help-create-largest-immune-cell-atlas-of-bone-marrow-in-multiple-myeloma-patients/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>RNA-MosaicHunterâ€”â€”ä»æ‰¹é‡RNAæµ‹åºæ•°æ®ä¸­ç²¾ç¡®æ£€æµ‹ä½“ç»†èƒå•æ ¸è‹·é…¸å˜å¼‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šRNA-MosaicHunter leverages RNA sequencing to accurately detect somatic single-nucleotide variants, revealing elevated mutation burdens in Alzheimerâ€™s cortex and offering insights into variant roles across tissues...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/rna-mosaichunter-accurate-detection-of-somatic-single-nucleotide-variants-from-bulk-rna-seq-data/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA-seq</td>
<td>15</td>
</tr>
<tr>
<td>cancer</td>
<td>7</td>
</tr>
<tr>
<td>ATAC-seq</td>
<td>7</td>
</tr>
<tr>
<td>methylation</td>
<td>6</td>
</tr>
<tr>
<td>metabolism</td>
<td>5</td>
</tr>
<tr>
<td>glioma</td>
<td>4</td>
</tr>
<tr>
<td>Hi-C</td>
<td>4</td>
</tr>
<tr>
<td>immune</td>
<td>3</td>
</tr>
<tr>
<td>histone</td>
<td>3</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>3</td>
</tr>
<tr>
<td>scRNA</td>
<td>3</td>
</tr>
<tr>
<td>T cell</td>
<td>2</td>
</tr>
<tr>
<td>single-cell</td>
<td>2</td>
</tr>
<tr>
<td>metabolic</td>
<td>2</td>
</tr>
<tr>
<td>macrophage</td>
<td>2</td>
</tr>
<tr>
<td>sequencing</td>
<td>2</td>
</tr>
<tr>
<td>transcriptome</td>
<td>2</td>
</tr>
<tr>
<td>tumor</td>
<td>2</td>
</tr>
<tr>
<td>spatial</td>
<td>1</td>
</tr>
<tr>
<td>spatial transcriptomics</td>
<td>1</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (59æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277396" target="_blank" rel="noopener noreferrer">GSE277396 åŸä»£å°èƒ¶è´¨ç»†èƒè„‚è´¨ä»£è°¢ï¼ˆscRNA-Seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271037" target="_blank" rel="noopener noreferrer">GSE271037 è„¾è„å’Œè„Šé«“Tç»†èƒçš„å•ç»†èƒRNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316044" target="_blank" rel="noopener noreferrer">GSE316044 é€šè¿‡ RNA-seq åˆ†æï¼Œç ”ç©¶äº†åœ¨å«è¡€æ¸…åŸ¹å…»åŸºå’Œæ·»åŠ å°åˆ†å­çš„æ— è¡€æ¸…åŸ¹å…»åŸºä¸­åŸ¹å…»çš„ç‰›è‚Œè‚‰å¹²ç»†èƒçš„è½¬å½•ç»„è°±ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306747" target="_blank" rel="noopener noreferrer">GSE306747 RHOA æ§åˆ¶ä¾µè¢­æ€§æ·‹å·´ç˜¤ä¸­çš„è‡´ç™Œ B ç»†èƒå—ä½“ä¿¡å·ä¼ å¯¼</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315878" target="_blank" rel="noopener noreferrer">GSE315878 åŒæºé‡ç»„åŠŸèƒ½æ­£å¸¸çš„åˆ—è…ºç™Œä¸­ARé¶å‘æ²»ç–—ä¸PARPæŠ‘åˆ¶å‰‚ä¹‹é—´ç¼ºä¹ååŒä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312061" target="_blank" rel="noopener noreferrer">GSE312061 è‚è„ç‰¹å¼‚æ€§é€’é€MDM2åä¹‰å¯¡æ ¸è‹·é…¸å¯å¯¹æŠ—é¥®é£Ÿè¯±å¯¼çš„ä»£è°¢åŠŸèƒ½éšœç¢ç›¸å…³çš„è„‚è‚ªè‚ç–¾ç—…</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308667" target="_blank" rel="noopener noreferrer">GSE308667 DAXX æŒ‡å¯¼ç²¾å­å‘ç”Ÿè¿‡ç¨‹ä¸­ H3.4 å‘ H3.3 ç»„è›‹ç™½çš„æ›¿æ¢</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308004" target="_blank" rel="noopener noreferrer">GSE308004 DAXX æŒ‡å¯¼ç²¾å­å‘ç”Ÿè¿‡ç¨‹ä¸­ H3.4 åˆ° H3.3 ç»„è›‹ç™½çš„æ›¿æ¢ [Cut &amp; Run]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297435" target="_blank" rel="noopener noreferrer">GSE297435 åŸºäº dCas9 çš„ DNA ç”²åŸºåŒ–ç¼–è¾‘ç³»ç»Ÿçš„ç‰¹å¼‚æ€§å’Œç¨³å®šæ€§çš„ç³»ç»Ÿæ¯”è¾ƒ [RNAseq_secondRun]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297432" target="_blank" rel="noopener noreferrer">GSE297432 åŸºäº dCas9 çš„ DNA ç”²åŸºåŒ–ç¼–è¾‘ç³»ç»Ÿçš„ç‰¹å¼‚æ€§å’Œç¨³å®šæ€§çš„ç³»ç»Ÿæ¯”è¾ƒ [äºšç¡«é…¸æ°¢ç›æµ‹åºï¼ˆç®€åŒ–è¡¨ç¤ºï¼‰_TMS2]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297430" target="_blank" rel="noopener noreferrer">GSE297430 åŸºäº dCas9 çš„ DNA ç”²åŸºåŒ–ç¼–è¾‘ç³»ç»Ÿçš„ç‰¹å¼‚æ€§å’Œç¨³å®šæ€§çš„ç³»ç»Ÿæ¯”è¾ƒ [RNAseq_firstRun]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297389" target="_blank" rel="noopener noreferrer">GSE297389 åŸºäº dCas9 çš„ DNA ç”²åŸºåŒ–ç¼–è¾‘ç³»ç»Ÿçš„ç‰¹å¼‚æ€§å’Œç¨³å®šæ€§çš„ç³»ç»Ÿæ¯”è¾ƒ [äºšç¡«é…¸æ°¢ç›æµ‹åºï¼ˆç®€åŒ–è¡¨ç¤ºï¼‰_TMS1]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297385" target="_blank" rel="noopener noreferrer">GSE297385 åŸºäº dCas9 çš„ DNA ç”²åŸºåŒ–ç¼–è¾‘ç³»ç»Ÿçš„ç‰¹å¼‚æ€§å’Œç¨³å®šæ€§çš„ç³»ç»Ÿæ¯”è¾ƒ [EPIC]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296999" target="_blank" rel="noopener noreferrer">GSE296999 ç”¨äºç ”ç©¶ä½“å†…é«˜å± BRAFV600E é©±åŠ¨çš„ç»“ç›´è‚ ç™Œçš„æ–°å‹åŒæºç»†èƒç³» [RNA-seq_organoids]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296998" target="_blank" rel="noopener noreferrer">GSE296998 ç”¨äºç ”ç©¶ä½“å†…é«˜å± BRAFV600E é©±åŠ¨çš„ç»“ç›´è‚ ç™Œçš„æ–°å‹åŒæºç»†èƒç³» [RNA-seq_NaJa]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296978" target="_blank" rel="noopener noreferrer">GSE296978 H4K16 é…°åŒ–ä½œç”¨å¾®è°ƒå¯¹çŸ­é“¾é…°åŸºè¾…é…¶Aè„±æ°¢é…¶ç¼ºä¹çš„è½¬å½•ååº”ï¼ˆRNA-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296977" target="_blank" rel="noopener noreferrer">GSE296977 H4K16é…°åŒ–ä½œç”¨å¾®è°ƒå¯¹çŸ­é“¾é…°åŸºè¾…é…¶Aè„±æ°¢é…¶ç¼ºä¹çš„è½¬å½•ååº”ï¼ˆChIP-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296976" target="_blank" rel="noopener noreferrer">GSE296976 H4K16 é…°åŒ–ä½œç”¨å¾®è°ƒå¯¹çŸ­é“¾é…°åŸºè¾…é…¶Aè„±æ°¢é…¶ç¼ºä¹çš„è½¬å½•ååº”ï¼ˆATAC-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275791" target="_blank" rel="noopener noreferrer">GSE275791 IDHçªå˜å‹èƒ¶è´¨ç˜¤èµ·æºäºæºå¸¦åˆå§‹é©±åŠ¨çªå˜çš„èƒ¶è´¨ç¥–ç»†èƒ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE274605" target="_blank" rel="noopener noreferrer">GSE274605 çªè§¦æ ¸è›‹ç™½ç—…æ¨¡å‹ä¸­èƒ½é‡ä»£è°¢æ”¹å˜å’Œæ˜¼å¤œèŠ‚å¾‹ç´Šä¹±çš„åˆ†å­ç‰¹å¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE202762" target="_blank" rel="noopener noreferrer">GSE202762 å—ä½“é…ªæ°¨é…¸æ¿€é…¶åœ¨ä¿¡å·å“åº”åŸºå› å¤„ç£·é…¸åŒ– RNA èšåˆé…¶ II [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE202761" target="_blank" rel="noopener noreferrer">GSE202761 å—ä½“é…ªæ°¨é…¸æ¿€é…¶åœ¨ä¿¡å·å“åº”åŸºå› å¤„ç£·é…¸åŒ– RNA èšåˆé…¶ II [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312072" target="_blank" rel="noopener noreferrer">GSE312072 ç­‰ä½åŸºå› æŸ“è‰²è´¨ç»“æ„æ˜¯å°è®°åŸŸçš„æ™®éç‰¹å¾ï¼Œå¹¶ä¸ Mest-Copg2 ä½ç‚¹çš„é¡ºå¼ä½œç”¨é•¿é“¾éç¼–ç  RNA ååŒå‘æŒ¥ä½œç”¨ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312071" target="_blank" rel="noopener noreferrer">GSE312071 ç­‰ä½åŸºå› æŸ“è‰²è´¨ç»“æ„æ˜¯å°è®°åŸŸçš„æ™®éç‰¹å¾ï¼Œå¹¶ä¸ Mest-Copg2 ä½ç‚¹çš„é¡ºå¼ä½œç”¨é•¿é“¾éç¼–ç  RNA ååŒä½œç”¨ [Capture Hi-C]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312069" target="_blank" rel="noopener noreferrer">GSE312069 ç­‰ä½åŸºå› æŸ“è‰²è´¨ç»“æ„æ˜¯å°è®°åŸŸçš„æ™®éç‰¹å¾ï¼Œå¹¶ä¸ Mest-Copg2 ä½ç‚¹çš„é¡ºå¼ä½œç”¨é•¿é“¾éç¼–ç  RNA ååŒå‘æŒ¥ä½œç”¨ [ATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308063" target="_blank" rel="noopener noreferrer">GSE308063 å¼¥æ¼«æ€§ä½çº§åˆ«å’Œé«˜çº§åˆ«èƒ¶è´¨ç˜¤ç»†èƒç³»ç”Ÿç‰©æ ·æœ¬åº“çš„ç‰¹å¾åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306737" target="_blank" rel="noopener noreferrer">GSE306737 è½¬å½•å› å­ Etv3 æ§åˆ¶æ ‘çªçŠ¶ç»†èƒçš„è€å—åŠŸèƒ½ï¼ˆæ¥è‡ªæ··åˆéª¨é«“åµŒåˆä½“çš„ Etv3 KO migDC çš„ RNA-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306682" target="_blank" rel="noopener noreferrer">GSE306682 è½¬å½•å› å­ Etv3 æ§åˆ¶æ ‘çªçŠ¶ç»†èƒçš„è€å—åŠŸèƒ½ï¼ˆEtv3 KO GM-DC çš„ RNA-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306680" target="_blank" rel="noopener noreferrer">GSE306680 è½¬å½•å› å­ Etv3 æ§åˆ¶æ ‘çªçŠ¶ç»†èƒçš„è€å—åŠŸèƒ½ï¼ˆEtv3 KO Tregs çš„ RNA-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306414" target="_blank" rel="noopener noreferrer">GSE306414 æ¢ç´¢å¼¥æ¼«æ€§ä½çº§åˆ«æ˜Ÿå½¢ç»†èƒç˜¤ç»†èƒç³» LGG275 ä¸­é™æ­¢æœŸ (P27+) å’Œæœ‰ä¸åˆ†è£‚æœŸ (P27-) èƒ¶è´¨ç˜¤ç»†èƒçš„åˆ†å­ç‰¹å¾å’Œç‰¹æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305451" target="_blank" rel="noopener noreferrer">GSE305451 æ­ç¤ºä½çº§åˆ«èƒ¶è´¨ç˜¤ç»†èƒç³»LGG275ä¸­æ˜Ÿå½¢èƒ¶è´¨ç»†èƒæ ·ç»†èƒå’Œå°‘çªèƒ¶è´¨ç»†èƒæ ·ç»†èƒçš„åˆ†å­ç‰¹å¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300165" target="_blank" rel="noopener noreferrer">GSE300165 é«˜é€šé‡æµ‹åºæ³•å¯¹è‚Œçƒè›‹ç™½VIè¿›è¡Œè¡¨è¾¾è°±åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286157" target="_blank" rel="noopener noreferrer">GSE286157ï¼šåŸ¹å…»6å¤©æœªç…§å°„æˆ–ç»20mGyç…§å°„çš„LT-HSCçš„HSPCè½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281655" target="_blank" rel="noopener noreferrer">GSE281655 é—ä¼ æ€§å†…è´¨ç½‘åº”æ¿€æŸå®³çº¿ç²’ä½“ä»£è°¢ï¼Œå¯¼è‡´ä½å‰‚é‡ç…§å°„é€ è¡€å¹²ç»†èƒè€—ç«­ [RREMseqHSC]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281654" target="_blank" rel="noopener noreferrer">GSE281654 é—ä¼ æ€§å†…è´¨ç½‘åº”æ¿€æŸå®³çº¿ç²’ä½“ä»£è°¢ï¼Œå¯¼è‡´ä½å‰‚é‡ç…§å°„é€ è¡€å¹²ç»†èƒè€—ç«­ [ATACseqHSC]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277426" target="_blank" rel="noopener noreferrer">GSE277426 æŸ“è‰²è´¨ç»„ç»‡å¯¹ I å‹å¹²æ‰°ç´ ååº”çš„è°ƒæ§ï¼ˆKO HoxB8-FL ç»†èƒçš„ ATAC-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277425" target="_blank" rel="noopener noreferrer">GSE277425 æŸ“è‰²è´¨ç»„ç»‡å¯¹ I å‹å¹²æ‰°ç´ ååº”çš„è°ƒæ§ï¼ˆIRF8 KO è„¾è„ pDC çš„ ATAC-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277424" target="_blank" rel="noopener noreferrer">GSE277424 æŸ“è‰²è´¨ç»„ç»‡å¯¹ I å‹å¹²æ‰°ç´ ååº”çš„è°ƒæ§ï¼ˆSMC3 KO pDC æ¿€æ´»çš„ RNA-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277423" target="_blank" rel="noopener noreferrer">GSE277423 æŸ“è‰²è´¨ç»„ç»‡å¯¹ I å‹å¹²æ‰°ç´ ååº”çš„è°ƒæ§ï¼ˆL929 æˆçº¤ç»´ç»†èƒ +/- SEV çš„ RNA-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277422" target="_blank" rel="noopener noreferrer">GSE277422 æŸ“è‰²è´¨ç»„ç»‡å¯¹ I å‹å¹²æ‰°ç´ ååº”çš„è°ƒæ§ï¼ˆIFN-I TB2/TB4 DKO FL-BMDC æ¿€æ´»çš„ RNA-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277289" target="_blank" rel="noopener noreferrer">GSE277289 é»è¿è›‹ç™½ä»‹å¯¼çš„æŸ“è‰²è´¨é‡å¡‘æ§åˆ¶ä¼ ç»Ÿæ ‘çªçŠ¶ç»†èƒçš„åˆ†åŒ–å’ŒåŠŸèƒ½ï¼ˆHoxb8-FL åˆ†åŒ–çš„ RAD21 å’Œ CTCF ChIP-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277288" target="_blank" rel="noopener noreferrer">GSE277288 æŸ“è‰²è´¨ç»„ç»‡å¯¹ I å‹å¹²æ‰°ç´ ååº”çš„è°ƒæ§ï¼ˆL929 æˆçº¤ç»´ç»†èƒ +/- SEV çš„ ATAC-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277287" target="_blank" rel="noopener noreferrer">GSE277287 æŸ“è‰²è´¨ç»„ç»‡å¯¹ I å‹å¹²æ‰°ç´ ååº”çš„è°ƒæ§ï¼ˆL929 æˆçº¤ç»´ç»†èƒçš„ Hi-C +/- SEVï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277284" target="_blank" rel="noopener noreferrer">GSE277284 é»è¿è›‹ç™½ä»‹å¯¼çš„æŸ“è‰²è´¨é‡å¡‘æ§åˆ¶ä¼ ç»Ÿæ ‘çªçŠ¶ç»†èƒçš„åˆ†åŒ–å’ŒåŠŸèƒ½ï¼ˆHoxB8-FL åˆ†åŒ–çš„ Hi-Cï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277283" target="_blank" rel="noopener noreferrer">GSE277283 é»è¿è›‹ç™½ä»‹å¯¼çš„æŸ“è‰²è´¨é‡å¡‘æ§åˆ¶ä¼ ç»Ÿæ ‘çªçŠ¶ç»†èƒçš„åˆ†åŒ–å’ŒåŠŸèƒ½ï¼ˆSMC3 KO FL-BMDC çš„ Hi-Cï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271283" target="_blank" rel="noopener noreferrer">GSE271283 é»è¿è›‹ç™½ä»‹å¯¼çš„æŸ“è‰²è´¨é‡å¡‘æ§åˆ¶ä¼ ç»Ÿæ ‘çªçŠ¶ç»†èƒçš„åˆ†åŒ–å’ŒåŠŸèƒ½ï¼ˆSMC3 KO è„¾è„ cDC çš„ RNA æµ‹åºï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271282" target="_blank" rel="noopener noreferrer">GSE271282 é»è¿è›‹ç™½ä»‹å¯¼çš„æŸ“è‰²è´¨é‡å¡‘æ§åˆ¶ä¼ ç»Ÿæ ‘çªçŠ¶ç»†èƒçš„åˆ†åŒ–å’ŒåŠŸèƒ½ï¼ˆIRF8 KO HoxB8-FL DCs çš„ RNA-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270821" target="_blank" rel="noopener noreferrer">GSE270821 æŸ“è‰²è´¨ç»„ç»‡å¯¹ I å‹å¹²æ‰°ç´ ååº”çš„è°ƒæ§ï¼ˆHoxB8-FL pDC æ¿€æ´»çš„ ATAC-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270816" target="_blank" rel="noopener noreferrer">GSE270816 é»è¿è›‹ç™½ä»‹å¯¼çš„æŸ“è‰²è´¨é‡å¡‘æ§åˆ¶ä¼ ç»Ÿæ ‘çªçŠ¶ç»†èƒçš„åˆ†åŒ–å’ŒåŠŸèƒ½ï¼ˆSMC3 KO FL-BMDC åˆ†åŒ–å’Œæ¿€æ´»çš„ RNA-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316074" target="_blank" rel="noopener noreferrer">GSE316074 å…ç–«æŠ‘åˆ¶å’Œç»†èƒåŠŸèƒ½éšœç¢çš„è½¬å½•ç»„ç‰¹å¾å¯åŒºåˆ†æ ‘çªçŠ¶ç»†èƒä¸­æ½œä¼å‹å’Œè½¬å½•æ´»è·ƒå‹ HIV-1 æ„ŸæŸ“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306618" target="_blank" rel="noopener noreferrer">GSE306618 æ·‹å·´ç³»ç»Ÿç´Šä¹±æ˜¯è‚ºç§»æ¤çº¤ç»´åŒ–çš„é©±åŠ¨å› ç´ </a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304876" target="_blank" rel="noopener noreferrer">GSE304876 Ramalin é€šè¿‡é¶å‘ BACE1ã€HDAC6 å’Œ MAPK é€šè·¯æ”¹å–„é˜¿å°”èŒ¨æµ·é»˜ç—…ç—…ç†</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303990" target="_blank" rel="noopener noreferrer">GSE303990 åŸ¹å…»çš„å°é¼ è§†ç½‘è†œç¥–ç»†èƒçš„è¡¨è§‚é—ä¼ å­¦å’Œè½¬å½•ç»„å­¦åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE276936" target="_blank" rel="noopener noreferrer">GSE276936 åŸä»£å°èƒ¶è´¨ç»†èƒçš„è„‚è´¨ä»£è°¢</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316149" target="_blank" rel="noopener noreferrer">GSE316149 å•æ ¸ç»†èƒè¡ç”Ÿçš„IL-10é©±åŠ¨ç–¼ç—›æŒç»­æ—¶é—´çš„æ€§åˆ«å·®å¼‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316046" target="_blank" rel="noopener noreferrer">GSE316046 åŒ…å«ä»å¯¹ç…§ç»„å’Œ DHEA å¤„ç†ç»„å°é¼ ä¸­åˆ†ç¦»çš„ CD8+ T ç»†èƒçš„å•ç»†èƒ RNA æµ‹åºæ•°æ®</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316039" target="_blank" rel="noopener noreferrer">GSE316039 ç ”ç©¶å‘ç° MGST3 ä¸‹è°ƒä¿ƒè¿›ç»“ç›´è‚ ç™Œè¿›å±•</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315814" target="_blank" rel="noopener noreferrer">GSE315814 NONO-HOXA1-Wntè½´åœ¨å¿ƒè‚Œç»†èƒåˆ†åŒ–ä¸­çš„å…³é”®ä½œç”¨[scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312736" target="_blank" rel="noopener noreferrer">GSE312736 è½¬å½•ç»„å­¦æ­ç¤ºäº†åœ¨é€æ¸æ°®ç¼ºä¹æ¡ä»¶ä¸‹ç´«çƒè—»çš„ä»£è°¢é‡ç¼–ç¨‹å’Œèƒå¤–å¤šç³–åˆæˆ</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-01-14 21:41</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>